About Us
About Us
Rafael Biotechnology Co., Ltd. was established in Hong Kong Special Administrative Region (HKSAR) of People’s Republic of China in 2018. We aim to develop, produce and marketing of affordable high-performance label-free biosensing instruments and cost effective consumables based on quantum plasmonic lab-on-chip (QPLoC) technology for biomedical research, drug discover and in-vitro diagnostics (IVD) purposes.
The QPLoC biosensor is the integration of the latest state-of-the-art materials science, nanotechnology, biochemistry and quantum optical metrology. It aims to fulfill the ever-increasing global demand for Molecular Diagnostics (MDx) and Companion Diagnostics (CDx) for emerging infectious diseases and oncology.
In view of the COVID-19 pandemic of past few years, in vitro diagnostic MDx toolkits should process four important characteristics i.e. multiprocessing, quick, precise, and cost-effective (MQPC). However, existing IVD toolkits much depends on polymerase chain reaction (PCR) for data analysis, and the PCR equipment are usually located in centralized laboratories. With surging demand for PCR tests, it quickly overloads the centralized facilities. So existing IVD products are far from MQPC perspective and on-site IVD toolkit with accurate and immediate result simply does not exist. The most disruptive technological breakthroughs of our QPLoC biosensor include,
- multiplex detection of over 100 viral genome fragments at once without PCR,
- quick label-free detection with thermoplasmonic effect in 15 minutes,
- precise SARS-CoV-2 viral genome measurement with attomole sensitivity i.e. 500 copies per mL,
- cost-effective biochip made of Titanium Nitride Nanocubes by 3D printing to replace gold material.
For oncology CDx, the QPLoC biosensor might detect exosomes excreted by specific tumor cells to the sensitivity of sub-picogram per milliliter. It should provide a non-invasive solution for early screening of cancer patients by liquid biopsy. So early treatment and intervention can be followed to increase the chance of patient survival. Our previous collaboration with local academic researchers has identified the feasibility of LSPR biosensor for detection of brain cancer exosomes by simple blood test [1, 2]. It demonstrated that exosomes can bypass the blood-brain-barrier (BBB) and circulates in the blood stream. We believe that exosomes released by other cancer cell can be detected in similar manner. On success of such diagnostic techniques, we believe the QPLoC biosensor shall save patients from intrusive tissue sample extraction and improves the healthcare of the general public against cancer diseases.
References